Theranica published a study showing its AI feature can predict a patient's next-day migraine risk with 91% precision. Drawing on 53,000 real-world Nerivio users, the study found a patient's own 30-day headache pattern was the strongest predictor of an attack.

Theranica announced that insurance coverage for Nerivio, its FDA-cleared migraine wearable, has now reached 158 million lives. It is now covered for half of the US insured population. Worn on the upper arm and controlled by a smartphone app, Nerivio uses remote electrical neuromodulation to activate the body's own pain-inhibitory pathways for both acute and preventive migraine treatment. Coverage has doubled over the past 15 months.